Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

iTeos Therapeutics Inc.

https://www.iteostherapeutics.com/

Latest From iTeos Therapeutics Inc.

Amicus Spins Out Rare Disease Gene Therapy Pipeline, Raises $200m

While Amicus will transfer the gene therapy portfolio’s R&D risk to Caritas, it retains a financial interest in many of the spinout’s programs. Pompe candidate AT-GAA accepted for FDA review.

Business Strategies Deals

Despite A Third Failure, Merck KGaA And GSK Won’t Give Up On Bintrafusp Yet

After three failures in quick succession, Merck needs to see a win in one of its many remaining Phase II trials.

Clinical Trials Companies

GSK Grows Immuno-Oncology Credentials With New Dostarlimab Indication

GlaxoSmithKline’s checkpoint inhibitor Jemperli has gained a second indication in the US, for the treatment of mismatch repair-deficient solid tumors, affirming the company’s drive to develop a new portfolio of cancer therapies.

Approvals ImmunoOncology

GSK Spends Heavily On iTeos' TIGIT To Build A New IO Cornerstone

GSK will pay iTeos $625m up front to codevelop and cocommercialize EOS-448, now in Phase I development for advanced solid tumors.

Cancer Deals
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Pharmaceuticals
    • Vaccines
  • Biotechnology
    • Large Molecule
      • Antibodies
    • Drug Discovery Tools
      • ADMET
UsernamePublicRestriction

Register